Posts Tagged: DAVID JENSEN

News

Rare stem cell success gives young girl life outside the bubble

Sheersha Sulack and Donald Kohn (with glasses) earlier this year on the day she received a cell treatment.

One year ago this month, five-year-old Sheersha Sulack asked Santa to bring her a suitcase to carry her toys with her for an arduous treatment that her parents hoped would save her from a rare, life-threatening affliction known as the bubble baby disease. Development of the therapy is part of a unique effort that has put the Golden State at the forefront of the development of gene and cell therapies.

News

Clinical trials okayed for children with ‘bubble boy’ disease

Andrea Fernandez and her son Jakob, who suffers from 'bubble boy' disease. (Photo: Courtesy of Fernandez family)

Nearly three years after a British firm abandoned a successful therapy for the life-threatening “bubble baby” disease, children will again be treated in a clinical trial backed with millions of dollars from the state of California. “It’s the best Christmas gift ever,” said the mother of an afflicted child, Andrea Fernandez. 

News

Stem cell: $137 million buys more clinical trials, shared labs, research

A laboratory scientist uses a pipette to manipulate stem cells. (Photo: Vshivkova, via Sutterstock)

It was a $137 million day for the Golden State’s stem cell agency — no small event even for an enterprise that is backed by billions. The scientific scope covered by the $137 million was impressive. It ranged from bolstering the vaunted Alpha Clinic Network initiated around the state by the California Institute for Regenerative Medicine (CIRM), as the agency is legally known, to raising the number of CIRM’s clinical trials to 83. 

News

Tiny budget piece could have huge impact on $12B stem cell agency

An illustration of the molecular structure of human cells and a researcher with vaccine. (Image: Billion Photos, Shutterstock)

A crack opened last week for the first time in 17 years in the firewall between state politicians and the $12 billion California stem cell agency. It involves only $600,000 — at least for now — and is buried deep in the 1,069-page state budget bill that was introduced June 8. But its implications are far-reaching. They range from opening the agency to major changes — wanted and unwanted — to creating a basis for the agency’s currently dubious, long-term financial sustainability.

News

“Killer cells” and conflicts at California’s stem cell agency

A laboratory pipette with fluid and test tubes for cancer research. (Photo: CI Photos, via Shutterstock)

Call it “The Case of the Killer Cells.”  It is an $8 million matter involving an effort by  California’s ambitious stem cell agency to develop cures for particularly tenacious and fatal cancers. The cash is snarled in an “embarrassing” conflict of interest, however, not to mention an irregular vote on the application for research funding from the stem cell agency.

News

State stem cell agency’s first royalties: $15 million from Stanford

Stanford University, where major stem cell research is being conducted.(Photo: yhelfman, via Shutterstock)

The California stem cell agency says it has received $15.6 million in royalties from Stanford University, the largest such payment by far in the 17-year history of the state research agency. Until the announcement, the agency, officially known as the California Institute for Regenerative Medicine (CIRM), had received only $557,292 in royalties.

News

Stem cell: UC’s odd ‘unmention’ in its top 10 research tales

Sather Gate at the University of California at Berkeley. (Photo: David A. Litman, via Shutterstock)

The University of California has identified its 10 best research stories of 2021, and right at the top is an article deeply involving the state’s $12 billion stem cell agency. The catch is that the stem cell agency was not even mentioned. That despite the fact that 13 persons with significant links to the University of California, including a UC regent, sit on the board that oversees the agency. 

News

Tangled tale: Research, profits and the ‘bubble baby’ syndrome

Evangelina, a former 'bubble baby,' plays inside a giant plastic bubble. (Photo: Stem Cellar Report, CIRM)

Little Evangelina Padilla-Vaccaro is more than a poster girl for the $12 billion California stem cell agency. She embodies a big bet by the agency that its efforts will conquer at least a few of the terrible diseases that are currently incurable. In the case of Evie, as the eight-year-old is known, she was born with what has come to be described as the bubble baby syndrome, a rare genetic mutation that crippled her immune system to the point that she would have died if left untreated.

News

UC Davis: First clinical trial of stem cells to treat spina bifida

A stem cell researcher at UC Davis. (Photo: AJ Cheline, UC Davis, via The Stem Cellar)

Backed by $17 million in cash from California’s stem cell agency, researchers at UC Davis this month are launching “the world’s first clinical trial using stem cells to treat spina bifida before the child is born.”

News

Recipient of $22 million from stem cell agency named to its board

Stem cell researcher and professor Larry Goldstein. (Photo: Screen capture, UCTV).

Larry Goldstein, a well-known stem cell researcher at the University of California, San Diego who has received nearly $22 million in awards from the California stem cell agency, today was named to its governing board. It was the first time in the history of the 16-year-old agency that a scientist who has received agency awards has been appointed to the board.

Support for Capitol Weekly is Provided by: